Davita - Lincoln Dialysis is a medicare approved dialysis facility center in Lincoln, Illinois and it has 14 dialysis stations. It is located in Logan county at 2100 West Fifth St, Lincoln, IL, 62656. You can reach out to the office of Davita - Lincoln Dialysis at (217) 732-6798. This dialysis clinic is managed and/or owned by Davita. Davita - Lincoln Dialysis has the following ownership type - Profit. It was first certified by medicare in January, 1998. The medicare id for this facility is 142582 and it accepts patients under medicare ESRD program.
| Name | Davita - Lincoln Dialysis |
|---|---|
| Location | 2100 West Fifth St, Lincoln, Illinois |
| No. of Dialysis Stations | 14 |
| Medicare ID | 142582 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2100 West Fifth St, Lincoln, Illinois, 62656 | |
| (217) 732-6798 | |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
| NPI Number | 1760441976 |
| Organization Name | Lincoln Dialysis |
| Doing Business As | Dva Renal Healthcare Inc |
| Address | 2100 5th St Lincoln, Illinois, 62656 |
| Phone Number | (217) 732-6798 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
| Dialysis patients with Hemoglobin data | 21 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 10 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 37 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 326 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - Lincoln Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 39 |
| Hypercalcemia patient months | 340 |
| Patients with Serumphosphor | 42 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 20 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 35 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 19 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 34 |
| Patient months included in arterial venous fistula and catheter summaries | 264 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 69 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 2 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 38 |
| Hospitalization Rate in facility | 134.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 276.3 |
| Hospitalization Rate: Lower Confidence Limit | 69.2 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - Lincoln Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 41.8 |
| Readmission Rate: Lower Confidence Limit | 10 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita - Lincoln Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 2.11 (As Expected) |
| SIR: Upper Confidence Limit | 4.68 |
| SIR: Lower Confidence Limit | .77 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita - Lincoln Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 38 |
| Transfusion Rate in facility | 26.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 112.3 |
| Transfusion Rate: Lower Confidence Limit | 7.5 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita - Lincoln Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 146 |
| Mortality Rate in facility | 13.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.2 |
| Mortality Rate: Lower Confidence Limit | 8.6 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago
Davita - Lincoln Dialysis Location: 2100 West Fifth St, Lincoln, Illinois, 62656 Phone: (217) 732-6798 |
News Archive
Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.
Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
› Verified 7 days ago